Clinical Trial Update: Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass [Phase 2]

View source ↗

Summary

Phase 2 trial of INS50589 intravenous infusion in subjects undergoing coronary artery bypass grafting was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• INS50589

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Coronary Disease | Phase 2 | Status: TERMINATED